Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5715699 | 0.96 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL809486 | 0.96 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| Potassium Ion SCHEMBL5672140 | 0.96 | TSHR (0.47) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Ammonia Solution, Strong SCHEMBL4761998 | 0.96 | TSHR (0.47) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| SCHEMBL5716311 | 0.96 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL7751336 | 0.96 | TSHR (0.47) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| SCHEMBL5715695 | 0.96 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL15799696 | 0.96 | TSHR (0.47) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| SCHEMBL5489526 | 0.96 | TSHR (0.47) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| SCHEMBL6271446 | 0.96 | TSHR (0.47) | TSHRTHRBLMNASLC22A1SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730156-A1 | PROCESS FOR PRODUCING TETRAKIS(FLUOROARYL)BORATE SALTS | ALBEMARLE CORPORATION (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005105816-A1 | PROCESS FOR PRODUCING TETRAKIS (FLUOROARYL) BORATE-SALTS | ALBEMARLE CORPORATION (US) | 2005-11-10 | — | — | WO | claimed |
| EP-1549656-A1 | PROCESS FOR PRODUCING TETRAKIS(\"F\"-ARYL)BORATE SALTS | ALBEMARLE CORPORATION (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004031197-A1 | PROCESS FOR PRODUCING TETRAKIS('F'-ARYL)BORATE SALTS | ALBEMARLE CORPORATION (US) | 2004-04-15 | — | — | WO | claimed |
| US-6388138-B1 | Process for producing a magnesium di[tetrakis(Faryl)borate] and products therefrom | ALBEMARLE CORPORATION | 2002-05-14 | — | — | US | claimed |
| WO-2001040235-A1 | PROCESS FOR PRODUCING DI-(TETRAKIS(FLUOROARYL)BORATO)-MAGNESIUM-SALTS AND CLATHRATES | ALBEMARLE CORPORATION (US) | 2001-06-07 | — | — | WO | claimed |
| US-6169208-B1 | Process for producing a magnesium di[tetrakis(Faryl)borate] and products therefrom | ALBEMARLE CORPORATION | 2001-01-02 | — | — | US | claimed |
| US-6162950-A | Preparation of alkali metal tetrakis(F aryl)borates | ALBEMARLE CORPORATION (US) | 2000-12-19 | — | — | US | claimed |
| WO-2000069869-A1 | POLYMERISATION CATALYSTS | BP CHEMICALS LIMITED (GB) | 2000-11-23 | — | — | WO | claimed |
| EP-3463584-B1 | THERAPEUTIC DENTAL PASTES AND THE APPLICATION THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11801231-B2 | Oral compositions and methods of use | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-10-31 | — | — | US | disclosed |
| US-11779446-B2 | Oral compositions and methods of use | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-10-10 | — | — | US | disclosed |
| CN-112739288-B | Dental appliance with cosmetically therapeutic aqueous solution | 3M创新有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11696879-B2 | Therapeutic dental pastes and related methods and kits | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-6388138-B1 | Process for producing a magnesium di[tetrakis(Faryl)borate] and products therefrom | ALBEMARLE CORPORATION | 2002-05-14 | — | — | US | disclosed |
| WO-2001042249-A1 | OLEFIN POLYMERIZATION COCATALYSTS DERIVED FROM GROUP-15 COMPOUNDS AND PROCESSES USING THEM | EXXON CHEMICAL PATENTS INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001040235-A1 | PROCESS FOR PRODUCING DI-(TETRAKIS(FLUOROARYL)BORATO)-MAGNESIUM-SALTS AND CLATHRATES | ALBEMARLE CORPORATION (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6169208-B1 | Process for producing a magnesium di[tetrakis(Faryl)borate] and products therefrom | ALBEMARLE CORPORATION | 2001-01-02 | — | — | US | disclosed |
| US-6162950-A | Preparation of alkali metal tetrakis(F aryl)borates | ALBEMARLE CORPORATION (US) | 2000-12-19 | — | — | US | disclosed |
| WO-2000069869-A1 | POLYMERISATION CATALYSTS | BP CHEMICALS LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696879-B2 | Therapeutic dental pastes and related methods and kits | PROC, DNASE1, COL2A1 | TSHR 4358/4885THRB 4213/4885LMNA 1536/4885 |
| US-11779446-B2 | Oral compositions and methods of use | PHOSPHO1, PWWP2B, PLCG2 | TSHR 4750/4885THRB 3431/4885LMNA 2029/4885 |
| US-11801231-B2 | Oral compositions and methods of use | HRH2, HRH3, TAS2R42 | TSHR 2030/4885THRB 1512/4885LMNA 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.